drugset / Trial / NCT01476904

Safety Study in Adolescent and Adult Patients With Asthma

NCT01476904

Phase 3 Completed 208 enrolled Amphastar Pharmaceuticals, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

E004-C2 is a continuation of E004-C for safety evaluations with additional 3 months to be able to assess the 6-month safety profile for E004 (epinephrine inhalation) versus placebo in a double-blinded manner.

Timeline

Start
2011-11
Primary completion
2012-04
Completion
2012-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Epinephrine Other / unclassified 125 ug Inhaled
Subject Epinephrine Other / unclassified 220 ug Inhaled

Indications